FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

被引:42
|
作者
Akita, H. [1 ]
Takahashi, H. [1 ]
Ohigashi, H. [2 ]
Tomokuni, A. [1 ]
Kobayashi, S. [1 ]
Sugimura, K. [1 ]
Miyoshi, N. [1 ]
Moon, J. -H. [1 ]
Yasui, M. [1 ]
Omori, T. [1 ]
Miyata, H. [1 ]
Ohue, M. [1 ]
Fujiwara, Y. [1 ]
Yano, M. [1 ]
Ishikawa, O. [1 ]
Sakon, M. [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis OMCC, Dept Surg, Osaka, Japan
[2] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan
来源
EJSO | 2017年 / 43卷 / 06期
关键词
Pancreatic cancer; Neoadjuvant; Chemoradiotherapy; FDG-PET; POSITRON-EMISSION-TOMOGRAPHY; GEMCITABINE-BASED CHEMORADIATION; PATHOLOGICAL RESPONSE; ADENOCARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; RECURRENCE; PACLITAXEL; MANAGEMENT;
D O I
10.1016/j.ejso.2017.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) for resectable and borderline resectable pancreatic cancer is important for predicting outcomes after radical surgery, but few clinical indicators predict outcome before resection. This study examined the utility of FDG-PET in predicting the efficacy of NACRT and outcome after radical surgery. Methods: Eighty-three pancreatic cancer patients who underwent FDG-PET before and after NACRT and had positive standard uptake values (SUVs) before NACRT were enrolled in this study. Peri-operative clinical factors, including FDG-PET findings, were examined to predict the efficacy of NACRT and outcome after surgery. Results: Evans grade I, IIA, [03, III, and IV was determined in 11, 31, 27, 11, and 3 patients, respectively. The maximum SUVs after NACRT (post SUV-max) and tumor size were significantly decreased compared to pretreatment values (p < 0.001 and p = 0.007, respectively). The post SUV-max and regression index were significantly related to grade III/IV (p = 0.04 and p < 0.001, respectively), but only the regression index predicted NACRT efficacy (p = 0.002). The AUC of the regression index for the detection of grade III/IV was 0.822, and 13 of 14 grade lII/IV patients were picked up using 50% as the threshold (p < 0.001). Patients with a regression index >50% had a significantly better prognosis after radical resection than patients with <50% (p = 0.032). Regression index as well as pathological lymph node status and resectability status were independent prognostic factors in multivariate analysis (exp 2.086, p = 0.043). Conclusion: The regression index is potentially a good indicator of the efficacy of NACRT and outcome after radical resection for pancreatic cancer. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 50 条
  • [1] The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer
    Crane, CH
    Varadhachary, G
    Wolff, RA
    Pisters, PWT
    Evans, DB
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2006, 20 (02) : 365 - 382
  • [2] FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
    Abdelrahman, Amro M.
    Goenka, Ajit H.
    Alva-Ruiz, Roberto
    Yonkus, Jennifer A.
    Leiting, Jennifer L.
    Graham, Rondell P.
    Merrell, Kenneth W.
    Thiels, Cornelius A.
    Hallemeier, Christopher L.
    Warner, Susanne G.
    Haddock, Michael G.
    Grotz, Travis E.
    Tran, Nguyen H.
    Smoot, Rory L.
    Ma, Wen Wee
    Cleary, Sean P.
    McWilliams, Robert R.
    Nagorney, David M.
    Halfdanarson, Thorvardur R.
    Kendrick, Michael L.
    Truty, Mark J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (09): : 1023 - +
  • [3] Preoperative Gemcitabine-based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
    Ravikumar, Reena
    Fusai, Giuseppe
    ANNALS OF SURGERY, 2015, 262 (06) : E103 - E103
  • [4] Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer
    de Jong, Tonke L.
    Koopman, Danielle
    van der Worp, Corne A. J.
    Stevens, Henk
    Vuijk, Floris A.
    Vahrmeijer, Alexander L.
    Mieog, J. Sven D.
    de Groot, Jan-Willem B.
    Meijssen, Maarten A. C.
    Nieuwenhuijs, Vincent B.
    Lioe-Fee, de Geus-Oei
    Jager, Pieter L.
    Patijn, Gijs A.
    SURGICAL ONCOLOGY-OXFORD, 2023, 47
  • [5] Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
    Takahashi, Hidenori
    Ohigashi, Hiroaki
    Gotoh, Kunihito
    Marubashi, Shigeru
    Yamada, Terumasa
    Murata, Masayuki
    Ioka, Tatsuya
    Uehara, Hiroyuki
    Yano, Masahiko
    Ishikawa, Osamu
    ANNALS OF SURGERY, 2013, 258 (06) : 1040 - 1050
  • [6] Pre-treatment FDG-PET does not predict outcome in resectable oesophageal cancer patients
    Pillai, A.
    Davies, A. R.
    Sandhu, H.
    Sinha, P.
    Helme, S.
    Ramage, L.
    Deguara, J.
    Gossage, J. A.
    Botha, A. J.
    Mason, R. C.
    BRITISH JOURNAL OF SURGERY, 2013, 100 : 48 - 49
  • [7] Neoadjuvant Chemoradiation With Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (PCa)
    Kharofa, J. R.
    Kelly, T.
    Wood, C.
    George, B.
    Tsai, S.
    Ritch, P.
    Wiebe, L.
    Christians, K.
    Evans, D.
    Erickson, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S89 - S89
  • [8] Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer
    Suto, Hironobu
    Okano, Keiichi
    Oshima, Minoru
    Ando, Yasuhisa
    Matsukawa, Hiroyuki
    Takahashi, Shigeo
    Shibata, Toru
    Kamada, Hideki
    Kobara, Hideki
    Tsuji, Akihito
    Masaki, Tsutomu
    Suzuki, Yasuyuki
    PANCREAS, 2022, 51 (03) : 269 - 277
  • [9] Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET
    Westerterp, Marinke
    Omloo, Jikke M. T.
    Sloof, Gerrit W.
    Hulshof, Maarten C. C. M.
    Hoekstra, Otto S.
    Crezee, Hans
    Boellaard, Ronald
    Vervenne, Walter L.
    Ten Kate, Fiebo J. W.
    Van Lanschot, Jan J. B.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2006, 22 (02) : 149 - 160
  • [10] Outcome Following Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Stokes, J. B.
    Walters, D. M.
    Norris, N. J.
    Stelow, E. B.
    Rich, T. A.
    Weiss, G. R.
    De Lange, E. E.
    Adams, R. B.
    Bauer, T. W.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 : 80 - 80